Trade Associations
Here's a look at documents from national and international trade associations
Featured Stories
Whale Cloud Receives Frost & Sullivan's 2025 Asia-Pacific Technology Innovation Leadership Recognition for Excellence in AI-enabled OSS/BSS Solutions
SAN ANTONIO, Texas, Dec. 4 [Category: BizConsulting] -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, posted the following news release:
* * *
Whale Cloud Receives Frost & Sullivan's 2025 Asia-Pacific Technology Innovation Leadership Recognition for Excellence in AI-enabled OSS/BSS Solutions
*
San Antonio, TX December 5, 2025 Frost & Sullivan is pleased to announce that Whale Cloud has been recognized with the 2025 Asia-Pacific Technology Innovation Leadership Recognition in the AI-enabled OSS/BSS industry for its
... Show Full Article
SAN ANTONIO, Texas, Dec. 4 [Category: BizConsulting] -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, posted the following news release:
* * *
Whale Cloud Receives Frost & Sullivan's 2025 Asia-Pacific Technology Innovation Leadership Recognition for Excellence in AI-enabled OSS/BSS Solutions
*
San Antonio, TX December 5, 2025 Frost & Sullivan is pleased to announce that Whale Cloud has been recognized with the 2025 Asia-Pacific Technology Innovation Leadership Recognition in the AI-enabled OSS/BSS industry for itsoutstanding achievements in innovation, platform integration, and customer impact. This recognition highlights Whale Cloud's consistent leadership in driving measurable outcomes, strengthening its market position, and delivering AI innovation and customer-centric digital transformation. With AI increasingly driving solutions for customers, the company has proactively pre-empted some key challenges to ensure customers seamlessly benefit from use of AI.
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: business impact and strategic technology leverage. Whale Cloud excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale.
"Whale Cloud is well positioned to ride out a growth trajectory over the next three to five years. WhaleDI AI will do well in growing the use of AI orchestration within mobile services and other vertical industries," said Mei Lee Quah, Senior Director, ICT Research at Frost & Sullivan.
Guided by a long-term growth strategy centered on AI innovation, ecosystem partnerships, and customer success, Whale Cloud continues to lead in delivering end to end digital transformation across the Asia-Pacific region. Founded in 2003 and formerly known as ZTEsoft, the company has been building its big data and AI capabilities for many years. Today, Whale Cloud delivers cutting-edge OSS/BSS, cloud, big data, and AI-integrated solutions to communications service providers (CSPs), government agencies, and enterprises in over 80 countries. Its 19 global capability centers, including two dedicated to AI research and development, ensure sustained innovation and operational excellence.
Innovation remains central to Whale Cloud's approach. Its flagship WhaleDI AI platform exemplifies its customer-centric commitment, enabling automation, personalization, and operational intelligence across diverse industries. The platform addresses critical challenges such as fragmented data, slow service rollout, and limited personalization by integrating multimodal AI for predictive, generative, and preceptive decision-making. Strategically embedded across Whale Cloud's core offeringsincluding the ZSmart Digital OSS/BSS suite, cloud solutions, and smart city platformsWhaleDI AI enhances automation, optimizes customer journeys, and drives real-time intelligence at scale. The end-to-end integration of WhaleDI AI across platforms enables customers to leverage AI as embedded AI capabilities across all layers.
"This recognition reflects our long-term commitment to advancing AI-driven innovation across telecom operations. By embedding intelligence into our ZSmart Digital OSS/BSS solutions, we aim to help CSPs simplify complexity, enhance agility, and accelerate digital transformation. This award is a testament to the dedication of our teams and the trust of our customers and partners," said Steven Cho, CMO of Whale Cloud International.
Whale Cloud's ZSmart Digital OSS/BSS suite supports modular deployment, AI-driven orchestration, and predictive maintenance to deliver improved operational efficiency and reduced total cost of ownership (TCO) for CSPs. Complementary solutions, including Digital Marketing Cloud (DMC), Fiber as a Service (FaaS), and Intelligent Network & Service Operation Center (iNOC), extend AI-driven capabilities to customer engagement, fiber deployment, and network operations. Through strong partnerships with Alibaba Cloud, ZTE, and selected ecosystem including with Alipay+ Payment Tech, Whale Cloud continues to accelerate digital transformation services, and smart city initiatives across emerging markets in Asia-Pacific, Africa, and Latin America.
Frost & Sullivan commends Whale Cloud for setting a high standard in competitive strategy, technology innovation, and execution excellence. The company's vision, robust innovation pipeline, and customer-first culture are shaping the future of AI-enabled OSS/BSS and driving measurable results for service providers and enterprises worldwide.
Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition honors forward-thinking organizations that are redefining their industries through technological innovation and growth excellence.
About Whale Cloud
Whale Cloud is a leading technology company that specializes in the digital transformation of telecommunication service providers and other verticals. We provide mission-critical solutions and services in Telecom, FinTech, and E&G sectors. At Whale Cloud, we're passionate about creating frictionless experiences for customers and empowering their digital ambitions.
Contact:
Xu Dong
E: dong.xu51@iwhalecloud.com
About Ashley Shreve
Marketing Coordinator - Best Practices Recognition
Ashley.Weinkauf@frost.com@frost.com
Phone: +1.210.844.2505
View all posts by Ashley Shreve
Ashley Shreve
Marketing Coordinator - Best Practices Recognition
Ashley.Weinkauf@frost.com@frost.com
Phone: +1.210.844.2505
***
Original text here: https://www.frost.com/news/press-releases/whale-cloud-receives-frost-sullivans-2025-asia-pacific-technology-innovation-leadership-recognition-for-excellence-in-ai-enabled-oss-bss-solutions/
Next-Generation Targeted Alpha Therapy using Astatine Shows Promise in Thyroid Cancer Resistant to C
RESTON, Virginia, Dec. 4 [Category: Medical] -- The Society of Nuclear Medicine and Molecular Imaging issued the following news release:
* * *
Next-Generation Targeted Alpha Therapy using Astatine Shows Promise in Thyroid Cancer Resistant to C
*
Reston, VA (December 4, 2025) A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211 At (astatine) was both well-tolerated and effective, achieving
... Show Full Article
RESTON, Virginia, Dec. 4 [Category: Medical] -- The Society of Nuclear Medicine and Molecular Imaging issued the following news release:
* * *
Next-Generation Targeted Alpha Therapy using Astatine Shows Promise in Thyroid Cancer Resistant to C
*
Reston, VA (December 4, 2025) A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211 At (astatine) was both well-tolerated and effective, achievingdisease control without molecularly targeted drugs. The findings were published in the December issue of The Journal of Nuclear Medicine.
Beta-emitting radioactive iodine is the standard treatment for patients with recurrent or metastatic differentiated thyroid cancer (DTC) after total thyroidectomy. However, despite repeated administration, some patients experience disease progression and are classified as refractory to radioactive iodine. At that point, molecular-targeted agents, such as kinase inhibitors, are used to treat radioactive iodine-resistant DTC.
"Molecular-targeted agents can be challenging for patients to take, as they require daily oral administration and are associated with a high rate of adverse effects, including proteinuria and dermatologic toxicity," said Tadashi Watabe, MD, PhD, FANMB, nuclear medicine physician at the Graduate School of Medicine at the University of Osaka in Japan. "Therefore, there is a clinical need for next-generation radiopharmaceutical therapy with improved tolerability and efficacy that can be used to treat radioactive iodine-refractory patients."
To address this issue, Watabe and colleagues developed a targeted alpha-therapy using the radionuclide 211 At-NaAt. In a phase I clinical trial, they utilized a dose escalation model (1.25, 2.5, and 3.5 MBq/kg) to assess the adverse events, pharmacokinetics, absorbed dose, and therapeutic efficacy of a single intravenous dose of 211 At-NaAt in patients with radioactive iodine-refractory DTC. Response was evaluated by thyroglobulin measurement, CT imaging, and 131 I SPECT imaging.
The researchers found that targeted alpha-therapy using 211 At-NaAt can be safely administered to patients with DTC. Although dose-limiting toxicities were observed with the 3.5 MBq/kg dose, toxicities remained within a tolerable range. Preliminary evidence of efficacy was observed in some patients treated with either 2.5 or 3.5 MBq/kg, including thyroglobulin reductions of greater than 50 percent and decreased uptake in radioactive iodine-avid lesions on 131 I SPECT.
"Our findings provide the first evidence that 211 At based therapy is both feasible and therapeutically promising in patients who no longer respond to conventional radioactive iodine," stated Watabe. "Because 211 At (astatine) therapy may achieve disease control without requiring molecular targeted drugs, it has the potential to reduce treatment burden, limit adverse effects associated with systemic therapies, and broaden access to effective care for patients with refractory disease."
"In addition," he noted, " 211 At can be produced using accelerator cyclotrons, and its availability will expand globally as more production facilities come online. The successful clinical application of 211 At in this study marks an important milestone for the field, opening the door to widespread adoption of cyclotron-based alpha-therapy and accelerating future innovations in molecular imaging and targeted radionuclide therapy."
Figure: (Upper) Graphical abstract illustrating the concept of targeted alpha therapy using [ 211 At] NaAt in patients with radioactive iodinerefractory differentiated thyroid cancer (DTC). (Lower) Representative 131 I planar and SPECT/CT images in patient with follicular thyroid cancer with multiple bone metastases after administration of [ 211 At] NaAt (3.5 MBq/kg). 131 I accumulation in lumbar spine and sacral metastases almost disappeared over time.
The authors of " First-in-Human Study of [ 211 At]NaAt as Targeted a-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial) " include Tadashi Watabe and Noriyuki Tomiyama, Department of Radiology, Graduate School of Medicine, University of Osaka, Osaka, Japan, and Institute for Radiation Sciences, University of Osaka, Osaka, Japan; Kosuke Mukai, Tomoaki Hayakawa, Atsunori Fukuhara, Toru Takano, and Iichiro Shimomura, Department of Metabolic Medicine, Graduate School of Medicine, University of Osaka, Osaka, Japan; Sadahiro Naka, Department of Pharmacy, University of Osaka Hospital, Osaka, Japan; Hidetaka Sasaki and Takashi Kamiya, Department of Medical Technology, University of Osaka Hospital, Osaka, Japan; Yoshifumi Shirakami, Kazuhiro Ooe, and Atsushi Toyoshima, Institute for Radiation Sciences, University of Osaka, Osaka, Japan; Satoshi Shigeno, Department of Gastroenterology and Hepatology, Graduate School of Medicine, University of Osaka, Osaka, Japan, and Medical Innovation Center, University of Osaka Hospital, Osaka, Japan; Satomi Okamura and Kazuho Masumura, Medical Innovation Center, University of Osaka Hospital, Osaka, Japan; Eisuke Hida, Department of Biostatistics and Data Science, Graduate School of Medicine, University of Osaka, Osaka, Japan; Hiromitsu Haba, RIKEN Nishina Center for Accelerator-Based Science, Wako, Japan; and Kayako Isohashi, Department of Radiology, Graduate School of Medicine, University of Osaka, Osaka, Japan.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.
***
Original text here: https://snmmi.org/Web/News/Articles/Next-Generation-Targeted-Alpha-Therapy-using-Astatine-Shows-Promise-in-Thyroid-Cancer-Resistant-to-C
ITI Convenes U.S. and Indian Officials to Kick Off AI Impact Summit
WASHINGTON, Dec. 4 [Category: Computer Technology] -- The Information Technology Industry Council posted the following news release:
* * *
ITI Convenes U.S. and Indian Officials to Kick Off AI Impact Summit
*
WASHINGTON - Today, global tech trade association ITI, in partnership with India AI Mission and the Embassy of India in Washington, DC, hosted the U.S. State Department and industry leaders for a robust discussion on how AI can fuel economic growth and tech leadership. The conversation was an official pre-event of the upcoming AI Impact Summit in Delhi.
ITI's event featured fireside
... Show Full Article
WASHINGTON, Dec. 4 [Category: Computer Technology] -- The Information Technology Industry Council posted the following news release:
* * *
ITI Convenes U.S. and Indian Officials to Kick Off AI Impact Summit
*
WASHINGTON - Today, global tech trade association ITI, in partnership with India AI Mission and the Embassy of India in Washington, DC, hosted the U.S. State Department and industry leaders for a robust discussion on how AI can fuel economic growth and tech leadership. The conversation was an official pre-event of the upcoming AI Impact Summit in Delhi.
ITI's event featured firesidechats between ITI President and CEO Jason Oxman, Indian Ambassador to the United States His Excellency Vinay Kwatra, and Under Secretary for Economic Affairs at the U.S. Department of State Jacob Helberg.
"The upcoming AI Impact Summit in India is built on the guiding principles of People, Planet, and Progress," said Indian Ambassador to the United States His Excellency Vinay Kwatra. "We are bringing together governments and leading experts from 100 countries to shape actionable recommendations that ensure AI does not deepen global divides but delivers measurable, inclusive impact for all. For American companies, this Summit represents an important opportunity to co-create the future of open, safe, and equitable AI alongside India's unmatched scale, talent, and innovation ecosystempartnership that will define responsible leadership in the AI era."
"The United States is the world's largest economy and India is the world's most populous country. There are no limits to what America and India can achieve together," said Under Secretary for Economic Affairs at the U.S. Department of State Jacob Helberg. "Both stand as complementary partners in our shared efforts to secure and grow the AI economy. Our shared interests and values open new terrain for joint ventures across critical technology sectors. Today, we can write a new chapter in the history of human progress. I look forward to further discussions with my Indian counterparts at the upcoming AI Action Summit."
"To realize its fullest economic and societal benefit, AI policy requires strong international partnerships and global alignment. ITI and its member companies are at the forefront of both AI's development and global policies, partnering with key leaders around the world to ensure they harness the innovative technology," said ITI President and CEO Jason Oxman. "As we look ahead to the next major global convening on AI at the Impact Summit in Delhi, engaging with Trump Administration and Indian government officials cements the tech industry's critical role."
***
Original text here: https://www.itic.org/news-events/news-releases/iti-convenes-u-s-and-indian-officials-to-kick-off-ai-impact-summit
American Cancer Society Updates Cervical Cancer Screening Guideline: Major Changes Include Self-Collection for HPV Testing and Guidance on Exiting Screening
ATLANTA, Georgia, Dec. 4 [Category: Medical] -- The American Cancer Society posted the following news release:
* * *
American Cancer Society Updates Cervical Cancer Screening Guideline: Major Changes Include Self-Collection for HPV Testing and Guidance on Exiting Screening
*
ATLANTA, December 4, 2025 The American Cancer Society (ACS) released updated guidelines today for cervical cancer screening, reflecting advances in disease detection and accessibility in the United States. The updated guideline for women at average risk and individuals with a cervix at average risk introduces two key changes:
... Show Full Article
ATLANTA, Georgia, Dec. 4 [Category: Medical] -- The American Cancer Society posted the following news release:
* * *
American Cancer Society Updates Cervical Cancer Screening Guideline: Major Changes Include Self-Collection for HPV Testing and Guidance on Exiting Screening
*
ATLANTA, December 4, 2025 The American Cancer Society (ACS) released updated guidelines today for cervical cancer screening, reflecting advances in disease detection and accessibility in the United States. The updated guideline for women at average risk and individuals with a cervix at average risk introduces two key changes:self-collection of vaginal samples for human papillomavirus (HPV) testing as an option for cervical cancer screening, and provides new guidance on when individuals can safely exit screening for the disease. The update is published in a report in CA: A Cancer Journal for Clinicians, the flagship journal of ACS.
"These updated recommendations will help to improve compliance with screening and reduce the risk of cervical cancer," said Dr. Robert Smith, senior vice president, early cancer detection science at the American Cancer Society and senior author of the report. "They are made possible as we continue to evolve our approach to screening for cervical cancer, primarily through research advancements, and the development of self-collection tools to broaden access to screening."
Cervical cancer screening programs have been successful at dramatically decreasing cancer incidence by more than half since the mid-1970s. However, 13,360 cases are expected to be diagnosed in the U.S. this year, and an estimated 4,320 people will die from the disease, with racial and socioeconomic disparities continuing to contribute to this number.
ACS cervical cancer guidelines
ACS recommends that average-risk women and individuals with a cervix at average risk initiate cervical cancer screening at age 25 and undergo primary HPV testing every five years through age 65. Research has shown that long-lasting infection with certain types of HPV causes nearly all cervical cancers. If primary HPV testing is not available, individuals 25-65 years of age should be screened by co-testing with an HPV test in combination with a cytology (Pap) test every five years, or cytology testing alone every three years.
What's new?
For primary HPV testing, clinician-collected cervical specimens are preferred, but self-collected vaginal specimens are acceptable for cervical cancer screening. When self-collected vaginal specimens are HPV negative in the screening setting, repeat testing in three years is recommended.
For discontinuing screening, ACS recommends that an average risk woman, or an individual with a cervix at average risk, have negative primary HPV tests or negative co-testing using HPV tests and cytology testing at ages 60 and 65. If primary HPV tests or co-testing are not available, three consecutive negative cytology tests at the recommended screening interval, with the last test at age 65, are acceptable.
Why these changes?
The updated report is part of an ongoing guideline development process by ACS scientists and volunteers. ACS monitors medical and scientific literature for new evidence that may support a change in current guidelines or the development of new guidelines, and for information about cervical cancer screening that should be conveyed to clinicians and target populations. Recently, the Food and Drug Administration (FDA) approved HPV self-collection testing as a safe and effective new screening option.
Do these guidelines apply to all women?
ACS does NOT recommend screening for:
* Women under age 25 (cervical cancer is rare before age 25)
* Women older than age 65 who have had adequate prior screening and are not otherwise at high risk
* Women who have had a hysterectomy (with removal of the cervix), unless they have a history of high-grade precancerous lesions
"In addition to funding research to help reduce the risk of cervical cancer, ACS established the National Roundtable on Cervical Cancer (ACS NRTCC) in late 2022," Smith added. "The ACS NRTCC is a coordinated effort with the mission to accelerate the elimination of cervical cancer primarily by improving prevention and screening uptake and addressing health disparities."
The American Cancer Society's advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), continues to work at all levels of government to advocate for access to cervical cancer screenings.
"Geographic disparities continue to exist in cervical cancer incidence and mortality, with individuals living in rural areas more likely to be diagnosed with later-stage cervical cancer. Over 46 million, or 14%, of the U.S. population live in rural areas that often require the need to travel long distances to access health care," said Lisa Lacasse, president of the ACS CAN. "Self-collection options are a critical resource for these individuals and other underserved populations. ACS CAN remains committed to partnering with policymakers to strengthen access to cervical cancer screening and necessary follow-up care without added costs. This is an important step towards ending cancer as we know it, for everyone."
Today's published guideline report also includes a patient page supporting the new guideline. CA journal Patient Pages provide highly relevant, evidence-based medical content in a structured, concise format that addresses typical patient questions about diseases, their related symptoms, prevention, and treatment. This tool helps patients understand specific conditions and treatment options.
ACS researcher Dr. Deana Baptiste is a contributing author of the report.
Additional ACS Resources:
* Cervical Cancer Screening Guidelines
* Cervical Cancer Information
* HPV Vaccine Guidelines
* ACS CancerRisk360
About the American Cancer Society
The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram.
***
Original text here: https://pressroom.cancer.org/updated-cervical-cancer-screening-guidelines-2025
AAPS Expands Lawsuit Against the Biden Administration and Specialty Boards
TUCSON, Arizona, Dec. 4 -- The Association of American Physicians and Surgeons issued the following news release:
* * *
AAPS Expands Lawsuit Against the Biden Administration and Specialty Boards
Update 12/2/2025
AAPS Educational Foundation Files Brief of Appellants with U.S. Court of Appeals for the Fifth Circuit - https://aapsonline.org/judicial/aaps-v-abim-12-2-2025-brief.pdf
Record Excerpts - https://aapsonline.org/judicial/aaps-v-abim-12-2-2025-record-excerpts.pdf
Update 5/2/2025
AAPS Educational Foundation Filed Brief in Opposition to the Department of Homeland Security Motion to Stay
... Show Full Article
TUCSON, Arizona, Dec. 4 -- The Association of American Physicians and Surgeons issued the following news release:
* * *
AAPS Expands Lawsuit Against the Biden Administration and Specialty Boards
Update 12/2/2025
AAPS Educational Foundation Files Brief of Appellants with U.S. Court of Appeals for the Fifth Circuit - https://aapsonline.org/judicial/aaps-v-abim-12-2-2025-brief.pdf
Record Excerpts - https://aapsonline.org/judicial/aaps-v-abim-12-2-2025-record-excerpts.pdf
Update 5/2/2025
AAPS Educational Foundation Filed Brief in Opposition to the Department of Homeland Security Motion to StayDiscovery - https://aapsonline.org/judicial/aaps-v-abim-5-2-2025.pdf
Update 4/17/2025
AAPS Educational Foundation Filed Brief in Opposition to the Department of Homeland Security Motion to Dismiss - https://aapsonline.org/judicial/aaps-v-dhs-04-17-2025.pdf
Update 4/4/2025 - AAPS Educational Foundation Filed the Following Briefs in Opposition to Motions to Dismiss:
Opposition to ABIM Motion to Dismiss - https://aapsonline.org/judicial/aaps-v-abim-reply-brief-4-4-2025.pdf
Opposition to ABOG Motion to Dismiss - https://aapsonline.org/judicial/aaps-v-abog-reply-brief-4-4-2025.pdf
Opposition to ABFM Motion to Dismiss - https://aapsonline.org/judicial/aaps-v-abfm-reply-brief-4-4-2025.pdf
Update 1/29/2025 - AAPS Educational Foundation Files Amended Complaint - https://aapsonline.org/judicial/aaps-v-abim-1-29-2025.pdf
*
The Association of American Physicians and Surgeons Educational Foundation ("AAPS") filed on Monday an expansion to its federal lawsuit against the Biden Administration and board-certifying organizations that threatened to, and sometimes have, revoked board certifications of physicians based on their outspokenness on matters of public policy.
Physicians who advocated using ivermectin to treat COVID-19 have, for example, been retaliated against by revocation of their board certifications. In addition, a board-certified witness was testifying against abortion at a congressional hearing when she was threatened with retaliation against her board certification, the Amended Complaint states.
The lawsuit has been joined by three physicians victimized by such retaliation.
"Using nearly identical terminology and timing, Defendants have acted in an apparently coordinated manner to attain their common objective of censorship based on viewpoint," AAPS states in its Amended Complaint. Defendants are the American Board of Internal Medicine (ABIM), the American Board of Obstetrics & Gynecology (ABOG), the American Board of Family Medicine (ABFM) and the Biden Administration.
In this precedent-setting lawsuit, AAPS seeks to establish that ABIM, ABOG, and ABFM have engaged in "state action" in threatening or revoking physicians' board certifications, which are necessary to practice medicine in most hospitals. AAPS sets forth in its court filings multiple ways in which these board-certifying organizations should be deemed to be state actors, and thus prohibited by the First Amendment from discriminating based on viewpoint.
"This new form of censorship is more dangerous than prior infringements on freedom of speech," AAPS's attorney Andrew Schlafly observes. "The Biden Administration has also wrongly caused social media platforms to take down postings and videos."
The U.S. Court of Appeals for the Fifth Circuit ruled on June 3 in this case that there is a constitutional right to hear which is fully protected by the First Amendment. "When physicians are silenced by threats to revoke their board certification, that infringes on the constitutional right to hear what they have to say," Mr. Schlafly added.
AAPS Educational Foundation's lawsuit is pending in U.S. District Court in Galveston, No. 3:22-cv-240.
The Association of American Physicians and Surgeons Educational Foundation
sponsors conferences and subsidizes students' attendance.
* * *
About AAPS
Since 1943, AAPS has been dedicated to the highest ethical standards of the Oath of Hippocrates and to preserving the sanctity of the patient-physician relationship and the practice of private medicine.
* * *
Original text here: https://aapsonline.org/aaps-expands-lawsuit-against-the-biden-administration-and-specialty-boards/
[Category: Medical]
AANA Expands Its Leadership in Lifelong Learning and Professional Advancement, Welcoming Dr. Hallie D. Evans as Senior Director of Education and Professional Development
ROSEMONT, Illinois, Dec. 4 [Category: Nursing] -- The American Association of Nurse Anesthesiology issued the following news release:
* * *
AANA Expands Its Leadership in Lifelong Learning and Professional Advancement, Welcoming Dr. Hallie D. Evans as Senior Director of Education and Professional Development
*
Rosemont, Ill. The American Association of Nurse Anesthesiology (AANA) is excited to announce the hiring of Hallie D. Evans, DNP, CRNA, APRN, CNE, CHSE, FAANA, as Senior Director of Education and Professional Development, effective December 2025. In this role, Dr. Evans will lead strategic
... Show Full Article
ROSEMONT, Illinois, Dec. 4 [Category: Nursing] -- The American Association of Nurse Anesthesiology issued the following news release:
* * *
AANA Expands Its Leadership in Lifelong Learning and Professional Advancement, Welcoming Dr. Hallie D. Evans as Senior Director of Education and Professional Development
*
Rosemont, Ill. The American Association of Nurse Anesthesiology (AANA) is excited to announce the hiring of Hallie D. Evans, DNP, CRNA, APRN, CNE, CHSE, FAANA, as Senior Director of Education and Professional Development, effective December 2025. In this role, Dr. Evans will lead strategicinitiatives to strengthen professional growth, lifelong learning, and academic innovation for nurse anesthesiology across the nation.
"I am inspired to step into this role at AANA because it offers a powerful opportunity to expand the reach of innovative, evidence-based education on a national scale," she said. "What excites me most is the chance to integrate technology, creativity, and compassionate, learner-centered design into meaningful lifelong learning experiences that strengthen our workforce and advance the nurse anesthesiology profession."
Dr. Evans is a nationally recognized nurse anesthesia educator and innovator known for advancing transformative education, meaningful research, and collaborative learning environments. A thought leader in nurse anesthesiology education, program development, and faculty mentoring, her career has been shaped by a commitment to excellence, growth, and innovation.
Dr. Evans earned both her master's degree in nurse anesthesiology and her Doctor of Nursing Practice (DNP) from Florida International University (FIU), where she joined the faculty upon graduation. She is currently pursuing a PhD in nursing at Florida State University. Her research centers on the use of innovative methods to educate both stigmatized patient and student populations.
At the Middle Tennessee School of Anesthesia (MTSA), Dr. Evans created and served as the founding director of the nation's first accredited nurse anesthesia educator program and launched the Education Innovation Center. At MTSA, she also served as Director of the Doctoral Completion Program and Grant Director, leading initiatives that expanded access to doctoral education and strengthened institutional innovation.
As a Certified Nurse Educator (CNE), Dr. Evans has led the design of modern curricula and instructional models that incorporate micro-learning, stackable micro-credentials, active learning strategies, and wellness-integrated instruction. Her expertise includes simulation-based education, interprofessional collaboration, and culturally responsive teaching. She has guided multiple programs through successful accreditation cycles and remains engaged in global academic partnerships, including curriculum development and teaching initiatives with the Georgetown Public Hospital Corporation and University of Guyana.
In addition to her education leadership roles, Dr. Evans continues to practice clinically, bringing current, real-world perspective to AANA's work in professional development. She specializes in pairing forward-thinking approaches with a strong commitment to learner outcomes and the ongoing advancement of nurse anesthesiology.
"Dr. Evans brings a rare combination of educational vision, program-building expertise, and a deep commitment to the success of learners and faculty," said Shayne Haglum, PhD, CRNA, APRN, AANA's Chief Science and Practice Officer. "Her leadership and innovative approach will help advance AANA's education strategy and support the continued growth and excellence of our great profession."
***
Original text here: https://www.aana.com/news/aana-expands-its-leadership-in-lifelong-learning-and-professional-advancement-welcoming-dr-hallie-d-evans-as-senior-director-of-education-and-professional-development/
2026 Miami Boat Show Venue Changes Aimed to Elevate Exhibitor Success
CHICAGO, Illinois, Dec. 4 [Category: Business] -- The National Marine Manufacturers Association posted the following news release:
* * *
2026 Miami Boat Show Venue Changes Aimed to Elevate Exhibitor Success
*
The Discover Boating Miami International Boat Show returns Feb. 11-15 with a reimagined footprint and a renewed focus on delivering stronger value for exhibitors and the recreational boating industry. The 2026 Miami Boat Show is introducing a more connected layout across Miami Beach and downtown Miami, designed to enhance the exhibitor and consumer experience, improve boat show navigation
... Show Full Article
CHICAGO, Illinois, Dec. 4 [Category: Business] -- The National Marine Manufacturers Association posted the following news release:
* * *
2026 Miami Boat Show Venue Changes Aimed to Elevate Exhibitor Success
*
The Discover Boating Miami International Boat Show returns Feb. 11-15 with a reimagined footprint and a renewed focus on delivering stronger value for exhibitors and the recreational boating industry. The 2026 Miami Boat Show is introducing a more connected layout across Miami Beach and downtown Miami, designed to enhance the exhibitor and consumer experience, improve boat show navigationacross its venues, and strengthen visibility for brands.
A major update for 2026 is the debut of the Miami Beach Yacht Collection along Indian Creek on Collins Avenue. The new in-water yacht showcase brings a higher-profile presence to Miami Beach, offering a luxury setting intended to attract qualified buyers and spotlight premium product lines, while more seamlessly connecting to the show's main hub at the Miami Beach Convention Center.
The sailing community will also see continued investment with enhancements to Sailor's Cove, joining Superyacht Miami at IGY Yacht Haven Grande Miami. Expanded marina infrastructure and additional space will create a more dynamic hub for sailing exhibitors and attendees, providing opportunities for deeper engagement, on-water demos and new activations. There is also a new parking lot secured at Sailor's Cove, with Park & Ride available between locations to improve connectivity.
The Miami Beach Convention Center will continue as the anchor destination within the show's footprint, with transportation upgrades to improve flow and reduced travel time between show destinations.
For companies planning to increase their presence, introduce new products or join the Miami show for the first time, the redesigned layout creates new opportunities to stand out. Space remains available, though prime locations are filling quickly.
NMMA members interested in exhibiting at the 2026 show can contact the show team with Informa Markets. For more information, visit MiamiBoatShow.com.
***
Original text here: https://www.nmma.org/press/article/25319
